This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cixutumumab
DrugBank Accession Number
DB12250
Background

Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.

Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Cixutumumab
External IDs
  • IMC-A12

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Cixutumumab is a fully human monoclonal antibody that specifically targets the type 1 human insulin-like growth factor receptor (IGF-IR). Tumors have receptors for the insulin-like growth factor-1 (IGF-I), and it is thought that the presence of these receptors cause tumors to grow. Cixutumumab attaches to the receptors and may inhibit the growth of cancer cells.

TargetActionsOrganism
UInsulin-like growth factor 1 receptorNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

148 h (3 mg/kg dose level) 209 h (6mg/kg dose level)

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Cixutumumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Cixutumumab.
AducanumabThe risk or severity of adverse effects can be increased when Cixutumumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cixutumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Cixutumumab.
AmivantamabThe risk or severity of adverse effects can be increased when Cixutumumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Cixutumumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Cixutumumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Cixutumumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Cixutumumab.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2285XW22DR
CAS number
947687-12-9

References

General References
  1. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. [Article]
  2. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9. [Article]
PubChem Substance
347911304
Wikipedia
Cixutumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentMetastatic Esophageal Adenocarcinoma / Metastatic Esophageal Squamous Cell Carcinoma / Metastatic Gastroesophageal Junction Adenocarcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastroesophageal Junction Adenocarcinoma / Recurrent Oesophageal Adenocarcinoma / Recurrent Oesophageal squamous cell carcinoma / Stage IV Esophageal Cancer AJCC v71
2CompletedTreatmentAdenocarcinoma of the Prostate1
2CompletedTreatmentAdenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2CompletedTreatmentAdipocytic Sarcoma / Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) / Leiomyosarcoma (LMS) / Rhabdomyosarcomas / Synovial Sarcoma1
2CompletedTreatmentAdult Rhabdomyosarcoma / Adult Synovial Sarcoma / Childhood Hepatoblastoma / Childhood Synovial Sarcoma / Neuroectodermal Tumors / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adrenocortical Carcinoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Retinoblastoma, Recurrent1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAdvanced Adult Primary Liver Cancer / Hepatocellular Carcinoma, Adult Primary / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC) / Non-small Cell Lung Cancer (NSCLC), Recurrent / Stage IIIB Non Small Cell Lung Cancer1
2CompletedTreatmentCarcinoma / Neuroendocrine Tumours (NETs)1
2CompletedTreatmentChildhood Alveolar Soft Part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Gliosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Peripheral Nerve Sheath Tumor / Childhood Synovial Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma / Rhabdomyosarcomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein tyrosine kinase activity
Specific Function
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involv...
Gene Name
IGF1R
Uniprot ID
P08069
Uniprot Name
Insulin-like growth factor 1 receptor
Molecular Weight
154791.73 Da

Drug created at October 20, 2016 21:43 / Updated at February 21, 2021 18:53